Formycon AG
Research Formycon AG (FYB) on Bullrun: market cap EUR 325.89M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerFYB
- ExchangeXETRA
- CountryGermany
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 325.89M
- Financial periodFY2025
- RevenueEUR 44.48M
- Revenue growth-36.2%
- Net income-EUR 64.70M
- Free cash flow-EUR 44.11M
- Gross margin8.0%
Valuation Snapshot
latest market cap is EUR 325.89M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 44.48M | -EUR 64.70M | -EUR 44.11M | 8.0% | n/a | EUR 68.85M | EUR 9.56M | EUR 399.14M |
| FY2024 | EUR 69.67M | -EUR 125.67M | -EUR 53.16M | 21.3% | n/a | EUR 41.83M | EUR 10.59M | EUR 461.84M |
| FY2023 | EUR 77.70M | EUR 75.80M | -EUR 31.04M | 30.0% | 4.72 | EUR 27.04M | EUR 29.49M | EUR 502.75M |
| FY2022 | EUR 42.50M | EUR 35.99M | -EUR 45.64M | 28.4% | 2.59 | EUR 9.82M | EUR 29.31M | EUR 356.58M |
| FY2021 | n/a | n/a | n/a | n/a | -1.2 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | EUR 325.89M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Formycon AG
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Formycon AG's market cap?
Formycon AG's market capitalization is EUR 325.89M.
What does Formycon AG do?
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names.